Aimmune confirms $2B Nestle acquisition

On Monday, Aimmune Therapeutics announced that it had agreed to Nestle’s $2 billion dollar acquisition. Yahoo Finance’s Anjalee Khemlani sat down with Jayson Dallas, Aimmune’s CEO, to speak about the acquisition and about the peanut allergy treatment development.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top